Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I told you all. Light end of the tunnel finally coming. We should all thank for the baby formula f** up. The FDA being looked at a microscope now. By both parties. Enjoy the fireworks. It's going to be epic.
Finally we're done. CW and everybody else
who has 200,000 shares. congratulations we're all millionaires. It's sad when I invest in this company I didn't need any glasses to read any of your posts. Now I have to wear glasses to read any of your guys's post. What a long journey we all went through. Hope everybody will do well and invest to help the world be a better place. Once again congratulations to all the holders here. Diamond hands and tiger blood.see you all on the next run.
All the vax are getting covid. And coming back in three to four day. https://www.cnn.com/2022/04/27/health/paxlovid-covid-rebound/index.html
OMG ADVERSE EVENTS after taking the vaccine. Documents just came out of court order!!.
APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST
1p36 deletion syndrome;2-Hydroxyglutaric aciduria;5'nucleotidase increased;Acoustic
neuritis;Acquired C1 inhibitor deficiency;Acquired epidermolysis bullosa;Acquired epileptic
aphasia;Acute cutaneous lupus erythematosus;Acute disseminated encephalomyelitis;Acute
encephalitis with refractory, repetitive partial seizures;Acute febrile neutrophilic
dermatosis;Acute flaccid myelitis;Acute haemorrhagic leukoencephalitis;Acute
haemorrhagic oedema of infancy;Acute kidney injury;Acute macular outer retinopathy;Acute
motor axonal neuropathy;Acute motor-sensory axonal neuropathy;Acute myocardial
infarction;Acute respiratory distress syndrome;Acute respiratory failure;Addison's
disease;Administration site thrombosis;Administration site vasculitis;Adrenal
thrombosis;Adverse event following immunisation;Ageusia;Agranulocytosis;Air
embolism;Alanine aminotransferase abnormal;Alanine aminotransferase increased;Alcoholic
seizure;Allergic bronchopulmonary mycosis;Allergic oedema;Alloimmune
hepatitis;Alopecia areata;Alpers disease;Alveolar proteinosis;Ammonia abnormal;Ammonia increased;Amniotic cavity infection;Amygdalohippocampectomy;Amyloid arthropathy;Amyloidosis;Amyloidosis senile;Anaphylactic reaction;Anaphylactic shock;Anaphylactic transfusion reaction;Anaphylactoid reaction;Anaphylactoid shock;Anaphylactoid syndrome of pregnancy;Angioedema;Angiopathic
neuropathy;Ankylosing spondylitis;Anosmia;Antiacetylcholine receptor antibody positive;Anti-actin antibody positive;Anti-aquaporin-4 antibody positive;Anti-basal ganglia
antibody positive;Anti-cyclic citrullinated peptide antibody positive;Anti-epithelial antibody
positive;Anti-erythrocyte antibody positive;Anti-exosome complex antibody positive;AntiGAD antibody negative;Anti-GAD antibody positive;Anti-ganglioside antibody
positive;Antigliadin antibody positive;Anti-glomerular basement membrane antibody
positive;Anti-glomerular basement membrane disease;Anti-glycyl-tRNA synthetase antibody
positive;Anti-HLA antibody test positive;Anti-IA2 antibody positive;Anti-insulin antibody
increased;Anti-insulin antibody positive;Anti-insulin receptor antibody increased;Antiinsulin receptor antibody positive;Anti-interferon antibody negative;Anti-interferon antibody
positive;Anti-islet cell antibody positive;Antimitochondrial antibody positive;Anti-muscle
specific kinase antibody positive;Anti-myelin-associated glycoprotein antibodies
positive;Anti-myelin-associated glycoprotein associated polyneuropathy;Antimyocardial
antibody positive;Anti-neuronal antibody positive;Antineutrophil cytoplasmic antibody
increased;Antineutrophil cytoplasmic antibody positive;Anti-neutrophil cytoplasmic
antibody positive vasculitis;Anti-NMDA antibody positive;Antinuclear antibody
increased;Antinuclear antibody positive;Antiphospholipid antibodies
positive;Antiphospholipid syndrome;Anti-platelet antibody positive;Anti-prothrombin
antibody positive;Antiribosomal P antibody positive;Anti-RNA polymerase III antibody
positive;Anti-saccharomyces cerevisiae antibody test positive;Anti-sperm antibody
positive;Anti-SRP antibody positive;Antisynthetase syndrome;Anti-thyroid antibody
positive;Anti-transglutaminase antibody increased;Anti-VGCC antibody positive;AntiVGKC antibody positive;Anti-vimentin antibody positive;Antiviral prophylaxis;Antiviral
treatment;Anti-zinc transporter 8 antibody positive;Aortic embolus;Aortic
thrombosis;Aortitis;Aplasia pure red cell;Aplastic anaemia;Application site
thrombosis;Application site vasculitis;Arrhythmia;Arterial bypass occlusion;Arterial bypass
thrombosis;Arterial thrombosis;Arteriovenous fistula thrombosis;Arteriovenous graft site
stenosis;Arteriovenous graft thrombosis;Arteritis;Arteritis
Page 30
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000083
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 2
coronary;Arthralgia;Arthritis;Arthritis enteropathic;Ascites;Aseptic cavernous sinus
thrombosis;Aspartate aminotransferase abnormal;Aspartate aminotransferase
increased;Aspartate-glutamate-transporter deficiency;AST to platelet ratio index
increased;AST/ALT ratio abnormal;Asthma;Asymptomatic COVID19;Ataxia;Atheroembolism;Atonic seizures;Atrial thrombosis;Atrophic thyroiditis;Atypical
benign partial epilepsy;Atypical pneumonia;Aura;Autoantibody positive;Autoimmune
anaemia;Autoimmune aplastic anaemia;Autoimmune arthritis;Autoimmune blistering
disease;Autoimmune cholangitis;Autoimmune colitis;Autoimmune demyelinating
disease;Autoimmune dermatitis;Autoimmune disorder;Autoimmune
encephalopathy;Autoimmune endocrine disorder;Autoimmune enteropathy;Autoimmune eye
disorder;Autoimmune haemolytic anaemia;Autoimmune heparin-induced
thrombocytopenia;Autoimmune hepatitis;Autoimmune hyperlipidaemia;Autoimmune
hypothyroidism;Autoimmune inner ear disease;Autoimmune lung disease;Autoimmune
lymphoproliferative syndrome;Autoimmune myocarditis;Autoimmune myositis;Autoimmune
nephritis;Autoimmune neuropathy;Autoimmune neutropenia;Autoimmune
pancreatitis;Autoimmune pancytopenia;Autoimmune pericarditis;Autoimmune
retinopathy;Autoimmune thyroid disorder;Autoimmune thyroiditis;Autoimmune
uveitis;Autoinflammation with infantile enterocolitis;Autoinflammatory disease;Automatism
epileptic;Autonomic nervous system imbalance;Autonomic seizure;Axial
spondyloarthritis;Axillary vein thrombosis;Axonal and demyelinating
polyneuropathy;Axonal neuropathy;Bacterascites;Baltic myoclonic epilepsy;Band
sensation;Basedow's disease;Basilar artery thrombosis;Basophilopenia;B-cell
aplasia;Behcet's syndrome;Benign ethnic neutropenia;Benign familial neonatal
convulsions;Benign familial pemphigus;Benign rolandic epilepsy;Beta-2 glycoprotein
antibody positive;Bickerstaff's encephalitis;Bile output abnormal;Bile output
decreased;Biliary ascites;Bilirubin conjugated abnormal;Bilirubin conjugated
increased;Bilirubin urine present;Biopsy liver abnormal;Biotinidase deficiency;Birdshot
chorioretinopathy;Blood alkaline phosphatase abnormal;Blood alkaline phosphatase
increased;Blood bilirubin abnormal;Blood bilirubin increased;Blood bilirubin unconjugated
increased;Blood cholinesterase abnormal;Blood cholinesterase decreased;Blood pressure
decreased;Blood pressure diastolic decreased;Blood pressure systolic decreased;Blue toe
syndrome;Brachiocephalic vein thrombosis;Brain stem embolism;Brain stem
thrombosis;Bromosulphthalein test abnormal;Bronchial oedema;Bronchitis;Bronchitis
mycoplasmal;Bronchitis viral;Bronchopulmonary aspergillosis allergic;Bronchospasm;BuddChiari syndrome;Bulbar palsy;Butterfly rash;C1q nephropathy;Caesarean section;Calcium
embolism;Capillaritis;Caplan's syndrome;Cardiac amyloidosis;Cardiac arrest;Cardiac
failure;Cardiac failure acute;Cardiac sarcoidosis;Cardiac ventricular thrombosis;Cardiogenic
shock;Cardiolipin antibody positive;Cardiopulmonary failure;Cardio-respiratory
arrest;Cardio-respiratory distress;Cardiovascular insufficiency;Carotid arterial
embolus;Carotid artery thrombosis;Cataplexy;Catheter site thrombosis;Catheter site
vasculitis;Cavernous sinus thrombosis;CDKL5 deficiency disorder;CEC syndrome;Cement
embolism;Central nervous system lupus;Central nervous system vasculitis;Cerebellar artery
thrombosis;Cerebellar embolism;Cerebral amyloid angiopathy;Cerebral arteritis;Cerebral
artery embolism;Cerebral artery thrombosis;Cerebral gas embolism;Cerebral
microembolism;Cerebral septic infarct;Cerebral thrombosis;Cerebral venous sinus
thrombosis;Cerebral venous thrombosis;Cerebrospinal thrombotic
Page 31
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000084
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 3
tamponade;Cerebrovascular accident;Change in seizure presentation;Chest discomfort;ChildPugh-Turcotte score abnormal;Child-Pugh-Turcotte score
increased;Chillblains;Choking;Choking sensation;Cholangitis sclerosing;Chronic
autoimmune glomerulonephritis;Chronic cutaneous lupus erythematosus;Chronic fatigue
syndrome;Chronic gastritis;Chronic inflammatory demyelinating
polyradiculoneuropathy;Chronic lymphocytic inflammation with pontine perivascular
enhancement responsive to steroids;Chronic recurrent multifocal osteomyelitis;Chronic
respiratory failure;Chronic spontaneous urticaria;Circulatory collapse;Circumoral
oedema;Circumoral swelling;Clinically isolated syndrome;Clonic convulsion;Coeliac
disease;Cogan's syndrome;Cold agglutinins positive;Cold type haemolytic
anaemia;Colitis;Colitis erosive;Colitis herpes;Colitis microscopic;Colitis ulcerative;Collagen
disorder;Collagen-vascular disease;Complement factor abnormal;Complement factor C1
decreased;Complement factor C2 decreased;Complement factor C3 decreased;Complement
factor C4 decreased;Complement factor decreased;Computerised tomogram liver
abnormal;Concentric sclerosis;Congenital anomaly;Congenital bilateral perisylvian
syndrome;Congenital herpes simplex infection;Congenital myasthenic syndrome;Congenital
varicella infection;Congestive hepatopathy;Convulsion in childhood;Convulsions
local;Convulsive threshold lowered;Coombs positive haemolytic anaemia;Coronary artery
disease;Coronary artery embolism;Coronary artery thrombosis;Coronary bypass
thrombosis;Coronavirus infection;Coronavirus test;Coronavirus test negative;Coronavirus
test positive;Corpus callosotomy;Cough;Cough variant asthma;COVID-19;COVID-19
immunisation;COVID-19 pneumonia;COVID-19 prophylaxis;COVID-19 treatment;Cranial
nerve disorder;Cranial nerve palsies multiple;Cranial nerve paralysis;CREST
syndrome;Crohn's disease;Cryofibrinogenaemia;Cryoglobulinaemia;CSF oligoclonal band
present;CSWS syndrome;Cutaneous amyloidosis;Cutaneous lupus erythematosus;Cutaneous
sarcoidosis;Cutaneous vasculitis;Cyanosis;Cyclic neutropenia;Cystitis interstitial;Cytokine
release syndrome;Cytokine storm;De novo purine synthesis inhibitors associated acute
inflammatory syndrome;Death neonatal;Deep vein thrombosis;Deep vein thrombosis
postoperative;Deficiency of bile secretion;Deja vu;Demyelinating
polyneuropathy;Demyelination;Dermatitis;Dermatitis bullous;Dermatitis
herpetiformis;Dermatomyositis;Device embolisation;Device related thrombosis;Diabetes
mellitus;Diabetic ketoacidosis;Diabetic mastopathy;Dialysis amyloidosis;Dialysis membrane
reaction;Diastolic hypotension;Diffuse vasculitis;Digital pitting scar;Disseminated
intravascular coagulation;Disseminated intravascular coagulation in newborn;Disseminated
neonatal herpes simplex;Disseminated varicella;Disseminated varicella zoster vaccine virus
infection;Disseminated varicella zoster virus infection;DNA antibody positive;Double cortex
syndrome;Double stranded DNA antibody positive;Dreamy state;Dressler's syndrome;Drop
attacks;Drug withdrawal convulsions;Dyspnoea;Early infantile epileptic encephalopathy with
burst-suppression;Eclampsia;Eczema herpeticum;Embolia cutis medicamentosa;Embolic
cerebellar infarction;Embolic cerebral infarction;Embolic pneumonia;Embolic
stroke;Embolism;Embolism arterial;Embolism venous;Encephalitis;Encephalitis
allergic;Encephalitis autoimmune;Encephalitis brain stem;Encephalitis
haemorrhagic;Encephalitis periaxialis diffusa;Encephalitis post
immunisation;Encephalomyelitis;Encephalopathy;Endocrine disorder;Endocrine
ophthalmopathy;Endotracheal intubation;Enteritis;Enteritis leukopenic;Enterobacter
pneumonia;Enterocolitis;Enteropathic spondylitis;Eosinopenia;Eosinophilic
Page 32
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000085
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 4
fasciitis;Eosinophilic granulomatosis with polyangiitis;Eosinophilic
oesophagitis;Epidermolysis;Epilepsy;Epilepsy surgery;Epilepsy with myoclonic-atonic
seizures;Epileptic aura;Epileptic psychosis;Erythema;Erythema induratum;Erythema
multiforme;Erythema nodosum;Evans syndrome;Exanthema subitum;Expanded disability
status scale score decreased;Expanded disability status scale score increased;Exposure to
communicable disease;Exposure to SARS-CoV-2;Eye oedema;Eye pruritus;Eye
swelling;Eyelid oedema;Face oedema;Facial paralysis;Facial paresis;Faciobrachial dystonic
seizure;Fat embolism;Febrile convulsion;Febrile infection-related epilepsy syndrome;Febrile
neutropenia;Felty's syndrome;Femoral artery embolism;Fibrillary
glomerulonephritis;Fibromyalgia;Flushing;Foaming at mouth;Focal cortical resection;Focal
dyscognitive seizures;Foetal distress syndrome;Foetal placental thrombosis;Foetor
hepaticus;Foreign body embolism;Frontal lobe epilepsy;Fulminant type 1 diabetes
mellitus;Galactose elimination capacity test abnormal;Galactose elimination capacity test
decreased;Gamma-glutamyltransferase abnormal;Gamma-glutamyltransferase
increased;Gastritis herpes;Gastrointestinal amyloidosis;Gelastic seizure;Generalised onset
non-motor seizure;Generalised tonic-clonic seizure;Genital herpes;Genital herpes
simplex;Genital herpes zoster;Giant cell arteritis;Glomerulonephritis;Glomerulonephritis
membranoproliferative;Glomerulonephritis membranous;Glomerulonephritis rapidly
progressive;Glossopharyngeal nerve paralysis;Glucose transporter type 1 deficiency
syndrome;Glutamate dehydrogenase increased;Glycocholic acid increased;GM2
gangliosidosis;Goodpasture's syndrome;Graft
thrombosis;Granulocytopenia;Granulocytopenia neonatal;Granulomatosis with
polyangiitis;Granulomatous dermatitis;Grey matter heterotopia;Guanase increased;GuillainBarre syndrome;Haemolytic anaemia;Haemophagocytic
lymphohistiocytosis;Haemorrhage;Haemorrhagic ascites;Haemorrhagic
disorder;Haemorrhagic pneumonia;Haemorrhagic varicella syndrome;Haemorrhagic
vasculitis;Hantavirus pulmonary infection;Hashimoto's
encephalopathy;Hashitoxicosis;Hemimegalencephaly;Henoch-Schonlein purpura;HenochSchonlein purpura nephritis;Hepaplastin abnormal;Hepaplastin decreased;Heparin-induced
thrombocytopenia;Hepatic amyloidosis;Hepatic artery embolism;Hepatic artery flow
decreased;Hepatic artery thrombosis;Hepatic enzyme abnormal;Hepatic enzyme
decreased;Hepatic enzyme increased;Hepatic fibrosis marker abnormal;Hepatic fibrosis
marker increased;Hepatic function abnormal;Hepatic hydrothorax;Hepatic
hypertrophy;Hepatic hypoperfusion;Hepatic lymphocytic infiltration;Hepatic mass;Hepatic
pain;Hepatic sequestration;Hepatic vascular resistance increased;Hepatic vascular
thrombosis;Hepatic vein embolism;Hepatic vein thrombosis;Hepatic venous pressure
gradient abnormal;Hepatic venous pressure gradient increased;Hepatitis;Hepatobiliary scan
abnormal;Hepatomegaly;Hepatosplenomegaly;Hereditary angioedema with C1 esterase
inhibitor deficiency;Herpes dermatitis;Herpes gestationis;Herpes oesophagitis;Herpes
ophthalmic;Herpes pharyngitis;Herpes sepsis;Herpes simplex;Herpes simplex
cervicitis;Herpes simplex colitis;Herpes simplex encephalitis;Herpes simplex gastritis;Herpes
simplex hepatitis;Herpes simplex meningitis;Herpes simplex meningoencephalitis;Herpes
simplex meningomyelitis;Herpes simplex necrotising retinopathy;Herpes simplex
oesophagitis;Herpes simplex otitis externa;Herpes simplex pharyngitis;Herpes simplex
pneumonia;Herpes simplex reactivation;Herpes simplex sepsis;Herpes simplex
viraemia;Herpes simplex virus conjunctivitis neonatal;Herpes simplex visceral;Herpes virus
Page 33
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000086
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 5
infection;Herpes zoster;Herpes zoster cutaneous disseminated;Herpes zoster infection
neurological;Herpes zoster meningitis;Herpes zoster meningoencephalitis;Herpes zoster
meningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster necrotising
retinopathy;Herpes zoster oticus;Herpes zoster pharyngitis;Herpes zoster
reactivation;Herpetic radiculopathy;Histone antibody positive;Hoigne's syndrome;Human
herpesvirus 6 encephalitis;Human herpesvirus 6 infection;Human herpesvirus 6 infection
reactivation;Human herpesvirus 7 infection;Human herpesvirus 8
infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemia
benign monoclonal;Hyperglycaemic seizure;Hypersensitivity;Hypersensitivity
vasculitis;Hyperthyroidism;Hypertransaminasaemia;Hyperventilation;Hypoalbuminaemia;H
ypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve paralysis;Hypoglossal
nerve paresis;Hypoglycaemic seizure;Hyponatraemic seizure;Hypotension;Hypotensive
crisis;Hypothenar hammer syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4
lymphocytopenia;Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathic
neutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM nephropathy;IIIrd nerve
paralysis;IIIrd nerve paresis;Iliac artery embolism;Immune thrombocytopenia;Immunemediated adverse reaction;Immune-mediated cholangitis;Immune-mediated
cholestasis;Immune-mediated cytopenia;Immune-mediated encephalitis;Immune-mediated
encephalopathy;Immune-mediated endocrinopathy;Immune-mediated enterocolitis;Immunemediated gastritis;Immune-mediated hepatic disorder;Immune-mediated hepatitis;Immunemediated hyperthyroidism;Immune-mediated hypothyroidism;Immune-mediated
myocarditis;Immune-mediated myositis;Immune-mediated nephritis;Immune-mediated
neuropathy;Immune-mediated pancreatitis;Immune-mediated pneumonitis;Immune-mediated
renal disorder;Immune-mediated thyroiditis;Immune-mediated uveitis;Immunoglobulin G4
related disease;Immunoglobulins abnormal;Implant site thrombosis;Inclusion body
myositis;Infantile genetic agranulocytosis;Infantile spasms;Infected vasculitis;Infective
thrombosis;Inflammation;Inflammatory bowel disease;Infusion site thrombosis;Infusion site
vasculitis;Injection site thrombosis;Injection site urticaria;Injection site vasculitis;Instillation
site thrombosis;Insulin autoimmune syndrome;Interstitial granulomatous
dermatitis;Interstitial lung disease;Intracardiac mass;Intracardiac thrombus;Intracranial
pressure increased;Intrapericardial thrombosis;Intrinsic factor antibody abnormal;Intrinsic
factor antibody positive;IPEX syndrome;Irregular breathing;IRVAN syndrome;IVth nerve
paralysis;IVth nerve paresis;JC polyomavirus test positive;JC virus CSF test positive;Jeavons
syndrome;Jugular vein embolism;Jugular vein thrombosis;Juvenile idiopathic
arthritis;Juvenile myoclonic epilepsy;Juvenile polymyositis;Juvenile psoriatic
arthritis;Juvenile spondyloarthritis;Kaposi sarcoma inflammatory cytokine
syndrome;Kawasaki's disease;Kayser-Fleischer ring;Keratoderma blenorrhagica;Ketosisprone diabetes mellitus;Kounis syndrome;Lafora's myoclonic epilepsy;Lambl's
excrescences;Laryngeal dyspnoea;Laryngeal oedema;Laryngeal rheumatoid
arthritis;Laryngospasm;Laryngotracheal oedema;Latent autoimmune diabetes in adults;LE
cells present;Lemierre syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidase
increased;Leukoencephalomyelitis;Leukoencephalopathy;Leukopenia;Leukopenia
neonatal;Lewis-Sumner syndrome;Lhermitte's sign;Lichen planopilaris;Lichen planus;Lichen
sclerosus;Limbic encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver function
test abnormal;Liver function test decreased;Liver function test increased;Liver
induration;Liver injury;Liver iron concentration abnormal;Liver iron concentration
Page 34
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000087
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 6
increased;Liver opacity;Liver palpable;Liver sarcoidosis;Liver scan abnormal;Liver
tenderness;Low birth weight baby;Lower respiratory tract herpes infection;Lower respiratory
tract infection;Lower respiratory tract infection viral;Lung abscess;Lupoid hepatic
cirrhosis;Lupus cystitis;Lupus encephalitis;Lupus endocarditis;Lupus enteritis;Lupus
hepatitis;Lupus myocarditis;Lupus myositis;Lupus nephritis;Lupus pancreatitis;Lupus
pleurisy;Lupus pneumonitis;Lupus vasculitis;Lupus-like syndrome;Lymphocytic
hypophysitis;Lymphocytopenia neonatal;Lymphopenia;MAGIC syndrome;Magnetic
resonance imaging liver abnormal;Magnetic resonance proton density fat fraction
measurement;Mahler sign;Manufacturing laboratory analytical testing issue;Manufacturing
materials issue;Manufacturing production issue;Marburg's variant multiple
sclerosis;Marchiafava-Bignami disease;Marine Lenhart syndrome;Mastocytic
enterocolitis;Maternal exposure during pregnancy;Medical device site thrombosis;Medical
device site vasculitis;MELAS syndrome;Meningitis;Meningitis aseptic;Meningitis
herpes;Meningoencephalitis herpes simplex neonatal;Meningoencephalitis
herpetic;Meningomyelitis herpes;MERS-CoV test;MERS-CoV test negative;MERS-CoV test
positive;Mesangioproliferative glomerulonephritis;Mesenteric artery embolism;Mesenteric
artery thrombosis;Mesenteric vein thrombosis;Metapneumovirus infection;Metastatic
cutaneous Crohn's disease;Metastatic pulmonary
embolism;Microangiopathy;Microembolism;Microscopic polyangiitis;Middle East
respiratory syndrome;Migraine-triggered seizure;Miliary pneumonia;Miller Fisher
syndrome;Mitochondrial aspartate aminotransferase increased;Mixed connective tissue
disease;Model for end stage liver disease score abnormal;Model for end stage liver disease
score increased;Molar ratio of total branched-chain amino acid to tyrosine;Molybdenum
cofactor deficiency;Monocytopenia;Mononeuritis;Mononeuropathy
multiplex;Morphoea;Morvan syndrome;Mouth swelling;Moyamoya disease;Multifocal
motor neuropathy;Multiple organ dysfunction syndrome;Multiple sclerosis;Multiple sclerosis
relapse;Multiple sclerosis relapse prophylaxis;Multiple subpial transection;Multisystem
inflammatory syndrome in children;Muscular sarcoidosis;Myasthenia gravis;Myasthenia
gravis crisis;Myasthenia gravis neonatal;Myasthenic syndrome;Myelitis;Myelitis
transverse;Myocardial infarction;Myocarditis;Myocarditis post infection;Myoclonic
epilepsy;Myoclonic epilepsy and ragged-red fibres;Myokymia;Myositis;Narcolepsy;Nasal
herpes;Nasal obstruction;Necrotising herpetic retinopathy;Neonatal Crohn's disease;Neonatal
epileptic seizure;Neonatal lupus erythematosus;Neonatal mucocutaneous herpes
simplex;Neonatal pneumonia;Neonatal seizure;Nephritis;Nephrogenic systemic
fibrosis;Neuralgic amyotrophy;Neuritis;Neuritis cranial;Neuromyelitis optica pseudo
relapse;Neuromyelitis optica spectrum disorder;Neuromyotonia;Neuronal
neuropathy;Neuropathy peripheral;Neuropathy, ataxia, retinitis pigmentosa
syndrome;Neuropsychiatric lupus;Neurosarcoidosis;Neutropenia;Neutropenia
neonatal;Neutropenic colitis;Neutropenic infection;Neutropenic sepsis;Nodular rash;Nodular
vasculitis;Noninfectious myelitis;Noninfective encephalitis;Noninfective
encephalomyelitis;Noninfective oophoritis;Obstetrical pulmonary embolism;Occupational
exposure to communicable disease;Occupational exposure to SARS-CoV-2;Ocular
hyperaemia;Ocular myasthenia;Ocular pemphigoid;Ocular sarcoidosis;Ocular
vasculitis;Oculofacial paralysis;Oedema;Oedema blister;Oedema due to hepatic
disease;Oedema mouth;Oesophageal achalasia;Ophthalmic artery thrombosis;Ophthalmic
herpes simplex;Ophthalmic herpes zoster;Ophthalmic vein thrombosis;Optic neuritis;Optic
Page 35
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000088
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 7
neuropathy;Optic perineuritis;Oral herpes;Oral lichen planus;Oropharyngeal
oedema;Oropharyngeal spasm;Oropharyngeal swelling;Osmotic demyelination
syndrome;Ovarian vein thrombosis;Overlap syndrome;Paediatric autoimmune
neuropsychiatric disorders associated with streptococcal infection;Paget-Schroetter
syndrome;Palindromic rheumatism;Palisaded neutrophilic granulomatous
dermatitis;Palmoplantar keratoderma;Palpable
purpura;Pancreatitis;Panencephalitis;Papillophlebitis;Paracancerous pneumonia;Paradoxical
embolism;Parainfluenzae viral laryngotracheobronchitis;Paraneoplastic
dermatomyositis;Paraneoplastic pemphigus;Paraneoplastic thrombosis;Paresis cranial
nerve;Parietal cell antibody positive;Paroxysmal nocturnal haemoglobinuria;Partial
seizures;Partial seizures with secondary generalisation;Patient isolation;Pelvic venous
thrombosis;Pemphigoid;Pemphigus;Penile vein thrombosis;Pericarditis;Pericarditis
lupus;Perihepatic discomfort;Periorbital oedema;Periorbital swelling;Peripheral artery
thrombosis;Peripheral embolism;Peripheral ischaemia;Peripheral vein thrombus
extension;Periportal oedema;Peritoneal fluid protein abnormal;Peritoneal fluid protein
decreased;Peritoneal fluid protein increased;Peritonitis lupus;Pernicious anaemia;Petit mal
epilepsy;Pharyngeal oedema;Pharyngeal swelling;Pityriasis lichenoides et varioliformis
acuta;Placenta praevia;Pleuroparenchymal fibroelastosis;Pneumobilia;Pneumonia;Pneumonia
adenoviral;Pneumonia cytomegaloviral;Pneumonia herpes viral;Pneumonia
influenzal;Pneumonia measles;Pneumonia mycoplasmal;Pneumonia necrotising;Pneumonia
parainfluenzae viral;Pneumonia respiratory syncytial viral;Pneumonia viral;POEMS
syndrome;Polyarteritis nodosa;Polyarthritis;Polychondritis;Polyglandular autoimmune
syndrome type I;Polyglandular autoimmune syndrome type II;Polyglandular autoimmune
syndrome type III;Polyglandular disorder;Polymicrogyria;Polymyalgia
rheumatica;Polymyositis;Polyneuropathy;Polyneuropathy idiopathic progressive;Portal
pyaemia;Portal vein embolism;Portal vein flow decreased;Portal vein pressure
increased;Portal vein thrombosis;Portosplenomesenteric venous thrombosis;Post procedural
hypotension;Post procedural pneumonia;Post procedural pulmonary embolism;Post stroke
epilepsy;Post stroke seizure;Post thrombotic retinopathy;Post thrombotic syndrome;Post viral
fatigue syndrome;Postictal headache;Postictal paralysis;Postictal psychosis;Postictal
state;Postoperative respiratory distress;Postoperative respiratory failure;Postoperative
thrombosis;Postpartum thrombosis;Postpartum venous thrombosis;Postpericardiotomy
syndrome;Post-traumatic epilepsy;Postural orthostatic tachycardia syndrome;Precerebral
artery thrombosis;Pre-eclampsia;Preictal state;Premature labour;Premature
menopause;Primary amyloidosis;Primary biliary cholangitis;Primary progressive multiple
sclerosis;Procedural shock;Proctitis herpes;Proctitis ulcerative;Product availability
issue;Product distribution issue;Product supply issue;Progressive facial
hemiatrophy;Progressive multifocal leukoencephalopathy;Progressive multiple
sclerosis;Progressive relapsing multiple sclerosis;Prosthetic cardiac valve
thrombosis;Pruritus;Pruritus allergic;Pseudovasculitis;Psoriasis;Psoriatic
arthropathy;Pulmonary amyloidosis;Pulmonary artery thrombosis;Pulmonary
embolism;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary microemboli;Pulmonary
oil microembolism;Pulmonary renal syndrome;Pulmonary sarcoidosis;Pulmonary
sepsis;Pulmonary thrombosis;Pulmonary tumour thrombotic microangiopathy;Pulmonary
vasculitis;Pulmonary veno-occlusive disease;Pulmonary venous thrombosis;Pyoderma
gangrenosum;Pyostomatitis vegetans;Pyrexia;Quarantine;Radiation leukopenia;Radiculitis
Page 36
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000089
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 8
brachial;Radiologically isolated syndrome;Rash;Rash erythematous;Rash pruritic;Rasmussen
encephalitis;Raynaud's phenomenon;Reactive capillary endothelial proliferation;Relapsing
multiple sclerosis;Relapsing-remitting multiple sclerosis;Renal amyloidosis;Renal
arteritis;Renal artery thrombosis;Renal embolism;Renal failure;Renal vascular
thrombosis;Renal vasculitis;Renal vein embolism;Renal vein thrombosis;Respiratory
arrest;Respiratory disorder;Respiratory distress;Respiratory failure;Respiratory
paralysis;Respiratory syncytial virus bronchiolitis;Respiratory syncytial virus
bronchitis;Retinal artery embolism;Retinal artery occlusion;Retinal artery thrombosis;Retinal
vascular thrombosis;Retinal vasculitis;Retinal vein occlusion;Retinal vein thrombosis;Retinol
binding protein decreased;Retinopathy;Retrograde portal vein flow;Retroperitoneal
fibrosis;Reversible airways obstruction;Reynold's syndrome;Rheumatic brain
disease;Rheumatic disorder;Rheumatoid arthritis;Rheumatoid factor increased;Rheumatoid
factor positive;Rheumatoid factor quantitative increased;Rheumatoid lung;Rheumatoid
neutrophilic dermatosis;Rheumatoid nodule;Rheumatoid nodule removal;Rheumatoid
scleritis;Rheumatoid vasculitis;Saccadic eye movement;SAPHO
syndrome;Sarcoidosis;SARS-CoV-1 test;SARS-CoV-1 test negative;SARS-CoV-1 test
positive;SARS-CoV-2 antibody test;SARS-CoV-2 antibody test negative;SARS-CoV-2
antibody test positive;SARS-CoV-2 carrier;SARS-CoV-2 sepsis;SARS-CoV-2 test;SARSCoV-2 test false negative;SARS-CoV-2 test false positive;SARS-CoV-2 test negative;SARSCoV-2 test positive;SARS-CoV-2 viraemia;Satoyoshi
syndrome;Schizencephaly;Scleritis;Sclerodactylia;Scleroderma;Scleroderma associated
digital ulcer;Scleroderma renal crisis;Scleroderma-like reaction;Secondary
amyloidosis;Secondary cerebellar degeneration;Secondary progressive multiple
sclerosis;Segmented hyalinising vasculitis;Seizure;Seizure anoxic;Seizure cluster;Seizure
like phenomena;Seizure prophylaxis;Sensation of foreign body;Septic embolus;Septic
pulmonary embolism;Severe acute respiratory syndrome;Severe myoclonic epilepsy of
infancy;Shock;Shock symptom;Shrinking lung syndrome;Shunt thrombosis;Silent
thyroiditis;Simple partial seizures;Sjogren's syndrome;Skin swelling;SLE arthritis;Smooth
muscle antibody positive;Sneezing;Spinal artery embolism;Spinal artery thrombosis;Splenic
artery thrombosis;Splenic embolism;Splenic thrombosis;Splenic vein
thrombosis;Spondylitis;Spondyloarthropathy;Spontaneous heparin-induced
thrombocytopenia syndrome;Status epilepticus;Stevens-Johnson syndrome;Stiff leg
syndrome;Stiff person syndrome;Stillbirth;Still's disease;Stoma site thrombosis;Stoma site
vasculitis;Stress cardiomyopathy;Stridor;Subacute cutaneous lupus erythematosus;Subacute
endocarditis;Subacute inflammatory demyelinating polyneuropathy;Subclavian artery
embolism;Subclavian artery thrombosis;Subclavian vein thrombosis;Sudden unexplained
death in epilepsy;Superior sagittal sinus thrombosis;Susac's syndrome;Suspected COVID19;Swelling;Swelling face;Swelling of eyelid;Swollen tongue;Sympathetic
ophthalmia;Systemic lupus erythematosus;Systemic lupus erythematosus disease activity
index abnormal;Systemic lupus erythematosus disease activity index decreased;Systemic
lupus erythematosus disease activity index increased;Systemic lupus erythematosus
rash;Systemic scleroderma;Systemic sclerosis
pulmonary;Tachycardia;Tachypnoea;Takayasu's arteritis;Temporal lobe epilepsy;Terminal
ileitis;Testicular autoimmunity;Throat tightness;Thromboangiitis
obliterans;Thrombocytopenia;Thrombocytopenic
purpura;Thrombophlebitis;Thrombophlebitis migrans;Thrombophlebitis
Page 37
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000090
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 9
neonatal;Thrombophlebitis septic;Thrombophlebitis superficial;Thromboplastin antibody
positive;Thrombosis;Thrombosis corpora cavernosa;Thrombosis in device;Thrombosis
mesenteric vessel;Thrombotic cerebral infarction;Thrombotic microangiopathy;Thrombotic
stroke;Thrombotic thrombocytopenic purpura;Thyroid disorder;Thyroid stimulating
immunoglobulin increased;Thyroiditis;Tongue amyloidosis;Tongue biting;Tongue
oedema;Tonic clonic movements;Tonic convulsion;Tonic posturing;Topectomy;Total bile
acids increased;Toxic epidermal necrolysis;Toxic leukoencephalopathy;Toxic oil
syndrome;Tracheal obstruction;Tracheal oedema;Tracheobronchitis;Tracheobronchitis
mycoplasmal;Tracheobronchitis viral;Transaminases abnormal;Transaminases
increased;Transfusion-related alloimmune neutropenia;Transient epileptic
amnesia;Transverse sinus thrombosis;Trigeminal nerve paresis;Trigeminal
neuralgia;Trigeminal palsy;Truncus coeliacus thrombosis;Tuberous sclerosis
complex;Tubulointerstitial nephritis and uveitis syndrome;Tumefactive multiple
sclerosis;Tumour embolism;Tumour thrombosis;Type 1 diabetes mellitus;Type I
hypersensitivity;Type III immune complex mediated reaction;Uhthoff's
phenomenon;Ulcerative keratitis;Ultrasound liver abnormal;Umbilical cord
thrombosis;Uncinate fits;Undifferentiated connective tissue disease;Upper airway
obstruction;Urine bilirubin increased;Urobilinogen urine decreased;Urobilinogen urine
increased;Urticaria;Urticaria papular;Urticarial vasculitis;Uterine
rupture;Uveitis;Vaccination site thrombosis;Vaccination site vasculitis;Vagus nerve
paralysis;Varicella;Varicella keratitis;Varicella post vaccine;Varicella zoster
gastritis;Varicella zoster oesophagitis;Varicella zoster pneumonia;Varicella zoster
sepsis;Varicella zoster virus infection;Vasa praevia;Vascular graft thrombosis;Vascular
pseudoaneurysm thrombosis;Vascular purpura;Vascular stent thrombosis;Vasculitic
rash;Vasculitic ulcer;Vasculitis;Vasculitis gastrointestinal;Vasculitis necrotising;Vena cava
embolism;Vena cava thrombosis;Venous intravasation;Venous recanalisation;Venous
thrombosis;Venous thrombosis in pregnancy;Venous thrombosis limb;Venous thrombosis
neonatal;Vertebral artery thrombosis;Vessel puncture site thrombosis;Visceral venous
thrombosis;VIth nerve paralysis;VIth nerve paresis;Vitiligo;Vocal cord paralysis;Vocal cord
paresis;Vogt-Koyanagi-Harada disease;Warm type haemolytic anaemia;Wheezing;White
nipple sign;XIth nerve paralysis;X-ray hepatobiliary abnormal;Young's syndrome;Zika virus
associated Guillain Barre syndrome.
what the hell just happen. 18s again WHY!! Did RVV not get EUA? two months not looking at this and lost.
what the differences Bucillamine vs fluoxetine for covid?
Expanded Bucillamine Research As Possible XYAZF Variant treatment. Starting to look like a sam . hope not
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19
https://www.biospace.com/article/-the-second-wave-biopharma-players-still-in-the-covid-19-game/
WOW!! Treatments will require taking as many as 40 doses in 5 days. reduced the risk of hospitalization and death by 30% when taken within five days of symptom. And RVV is what? 100%!! 15 pills in 5 days. LMAO
“I look upon this as only the first generation” of such pills, said Dr. W. David Hardy of Charles Drew University School of Medicine and Science in Los Angeles, who voted to recommend the Merck drug. “We’ve had reports that there are better drugs coming down the pike that are also oral. . . . In the environment that we’re in, having additional medications, even if they’re not fantastic, is helpful.”
https://www.bostonglobe.com/2021/12/09/nation/covid-19-pills-at-home-use-are-likely-arrive-soon-they-come-with-drawbacks/
Wow!! GBS ( Guillain-Barre Symptoms) with COVID vaccination mRNA.
https://www.news-medical.net/news/20211208/CDC-study-shows-risk-of-Guillain-Barre-syndrome-elevated-after-Ad26COV2S-COVID-vaccination.aspx
The CEO of BioNTech, Ugur Sahin announced that in order to prevent the mild symptoms variant of COVID, we’d need to be injected with three more doses of the familiar vaccines, plus another initial vaccine, and a booster!
Get your six booster so you could get a heart attack.
I'm shocked as a Canadian company that's doing pretty well in the trials that we know of. Why isn't the Canadian government supporting this company or giving a grant. Even giving to their citizens and prove to the world that this drug works and it's safe than any therapeutic out there right now.
No doubt I thought we're going to run today at least get 20% up
We've been waiting almost 2 years. As we see other pills coming out to the market Ann rvv keep on delaying. It's getting very frustrated get the eua and let's move forward on the other test.WTF it feels like something's not right.
Heart risk after vaccines mRNA. We will see a large heart issue next year.
https://pubmed.ncbi.nlm.nih.gov/34846169/
Is today the day we see data?
259 Athlete Cardiac Arrests, 141 Die, After COVID Shot
https://goodsciencing.com/covid/71-athletes-suffer-cardiac-arrest-26-die-after-covid-shot/
Tik-Tok .17 is coming soon with a new high.
Coin Citadel 2021 Q3 financials have been filed. CPA has already begun reviewing/amending Q2, Q1 and 2020 years end. Once finished, a new attorney letter will be filed with OTC Markets.
What!! FDA says it needs 55 years to release Pfizer vaccine data
https://komonews.com/news/nation-world/fda-says-it-needs-55-years-to-release-pfizer-vaccine-data
If the study does well. And the resorts are great. We could see $120 price range. Then a drop to $50-$60.
I am shocked that this stock still in these levels with all the good news and data. We should be at least a dollar fifty.
Revive Therapeutics Ltd (OTCMKTS: RVVTF) Receives Go-Ahead From DSMB To Continue Study Evaluating Bucillamine in COVID-19 Treatment
https://factsaboutcbd.org/revive-therapeutics-ltd-otcmkts-rvvtf-receives-go-ahead-from-dsmb-to-continue-study-evaluating-bucillamine-in-covid-19-treatment-5251
WOW they got pushed back a year. I hope we don't get pushed back a year. We shouldn't be pushed back these drug have been around for 30 years.
medicinal mushrooms in the treatment of cancer of the breast discovered that a compound from the mushroom variety Ganoderma lucidum, which has an anticancer effect. This effect is especially significant against breast cancer and has the potential to treat the most aggressive types of breast cancers, such as triple-negative breast cancer and inflammatory breast cancer," the researchers remarked.
Holy Sh!T this is big news!! I did not know they are working with Ganoderma lucidum. F-ing a triple negative breast cancer and inflammatory breast cancer. The researchers remarked. RVVTF should be at $20 to $310 Just on curing breast cancer.
"UCC researchers to reach the commercialization phase."
https://medicinaysaludpublica.com/noticias/casos-clinicos/aprueban-patente-farmaceutica-para-estudio-de-hongo-medicinal-contra-cancer-triple-negativo-en-la-isla/11001
Patent discovery researcher and associate professor Dr. Michelle Martinez on the use of medicinal mushrooms in the treatment of cancer of the breast, was patented before the Trust for Science , Technology and Research Puerto Rico (PRSTRT), representing the Central University of the Caribbean ( UCC ) and the Canadian company Revive Therapeutics.
The research was shared with Dr. Fátima Rivas, from St. Jude Children 's Research Hospital ; after Dr. Martinez discovered that a compound from the mushroom variety Ganoderma lucidum, which has an anticancer effect.
"This effect is especially significant against breast cancer and has the potential to treat the most aggressive types of breast cancers, such as triple negative breast cancer and inflammatory breast cancer," the researchers remarked.
The elbow abscess was 4 days before the symptoms which lasted 15 days prior to arriving at the ER, it is read or I almost understand that the abscess presented in ER but it was not like that, at home he presented a small abscess that the patient refers opened and healthy at home without going to a doctor for evaluation
It is read that Patient was discharged very quickly, completed 15 days of IV antibiotics with marked improvement, then coordinated to fulfill the days that would be missing from IV antibiotics treatment to complete a minimum of 8 weeks.
Dr. Martínez noted that she began conducting research on the fungus Ganoderma lucidum in 2007 and that this represents the goal of every researcher dedicated to science and health.
Related article: Puerto Rican scientist demonstrates that medicinal mushroom suppresses the migration of triple negative breast cancer cells
"Having succeeded in getting a pharmaceutical company to develop a non-toxic therapeutic alternative for people suffering from this lethal cancer is a great achievement in my scientific career and as a person. This agreement represents the goal of every researcher: to discover new technologies that help human health . I want to highlight the support I received from the Central University of the Caribbean and the Trust's Technology Transfer Office to make this agreement possible, "said the researcher.
The director of the Trust's Office of Technology Transfer, Dr. David Gulley , said that this is the first successful license agreement that we have as a result of our collaboration with the UCC.
"The research team also participated in our 2021 Therapeutic Accelerator Program in cooperation with Columbia University, and received $ 75,000 from the Trust to de-risk the technology. Successful technology transfer begins with outstanding research," but it requires a team and resources to move toward commercialization, "he said.
For her part, the president of the UCC, Dr. Waleska Crespo, stated that "this agreement makes history at our institution as it is the first of the patents developed by UCC researchers to reach the commercialization phase. We are very excited about this achievement and we reaffirm our commitment to the development of knowledge through research, which is one of our institutional goals. "
About the patent
Revive Therapeutics, Ltd. exclusively licensed the international patent application under the name Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization. Revive Therapeutics is a life sciences company focused on the research and development of therapies for infectious diseases and rare disorders.
Dr. Martínez explained that the patent process began in 2019 with the support of the Trust's Technology Transfer Office (TTO) and that, after filing a provisional patent, an international patent application (PCT) was submitted. To seek to protect the invention internationally, and for it to be published, the license talks began in January of this year.
On August 9, the exclusive license agreement on the intellectual property of the discovery was signed.
COVID-19 vaccines are toxic go to 35:45
My god, we should be at $5 I hope India is going to make RVVTF go to the Moon. Because the FDA going to give us nothing.
go to 18:48 go info
this is So F up. It been 6 months and nothing. Even this news did nothing for the stock.
https://www.proactiveinvestors.com/companies/news/951701/revive-therapeutics-partners-with-india-based-specialty-pharma-supriya-lifescience-to-advance-bucillamine-to-treat-coronavirus-951701.html
WTH
"Two projects are currently relatively advanced, tested on more than a thousand people (“phase 3” clinical trials). " Why The F^$$@K Revive is not on this article. This is BS
Key manufacturers of Autoimmune Hepatitis Diagnosis and Treatment market by CAGR analysis includes:
Revive Therapeutics, Ltd.
Abbott Laboratories, Inc.
Bristol-Myers Squibb Co.
NIDDK
Pfizer, Inc.
Novartis International AG
Johns Hopkins Medicine
AbbVie, Inc.
Gilead Sciences, Inc.
AstraZeneca PLC
Principia Biopharma, Inc.
Inova Diagnostics, Inc.
Bio-Rad Laboratories, Inc.
Mayo Clinic
https://renewableenergyzone.com/uncategorized/187832/global-autoimmune-hepatitis-diagnosis-and-treatment-market-2020-2026-analysis-of-industry-strengths-and-challenges-during-the-covid-19/
CCTL to .20 then $1 You all missed the train. So sorry Next week the big boys are coming. More the US prints money the more money flowing to crypto world. Once COVID 19 comes back in the fall get the printing press ready again. US is at 30t by and of the year US will be 40T in debt. The US is worth only $60T. This is why it is the year of Crypto and silver.
CCTL will pay by SafeMoon and DOGET. WHERE IS THE DOG CCTL GOT SOME SAFEMOON SNACKS.
To the SafeMoon CCTL. BO at .20 coming.
I got 515 SafeMoon!
CCTL will take use to the safe moon.
Is CCTL using hydroelectric for mining? If so is CCTL the only hydroelectric?
This cctl CEO needs to go to jail. There was no meeting with the Attorney. He tweeted Sh!$tT that is not true. Now that his buddies sold their share funny how there is no new twitter updated.
Why is CCTL so low? If that is true 65million. CCTL easily should be at .25 just cash on hand. Help the shareholder buy back some stock!!
that's why the company needs to be current CE off.